申请人:Zyma SA
公开号:US04946861A1
公开(公告)日:1990-08-07
The invention relates to the use of ketenethioacetals of the formula ##STR1## in which R.sub.1 represents aryl or heteroaryl, R.sub.2 represents hydrogen, an optionally substituted hydrocarbon radical, heteroaryl, an acyl radical, a group of the formula --S(O).sub.m --R.sub.a, wherein m is 0, 1 or 2 and R.sub.a is an optionally substituted hydrocarbon radical; or optionally functionally modified sulpho, A represents an optionally substituted bivalent aliphatic hydrocarbon radical and n is 0 or 1, and pharmaceutically acceptable salts of such compounds that contains a salt-forming group, for the treatment of liver diseases, respiratory tract diseases and vascular diseases pharmaceutical preparations containing compounds of the formula I and novel compounds of the formula I. The compounds have liver-protecting and immunomodulating properties.
本发明涉及使用式为##STR1##的羰基硫缩醇醚,其中R.sub.1代表芳基或杂芳基,R.sub.2代表氢、可选取代的碳氢基团、杂芳基、酰基基团、公式--S(O).sub.m--R.sub.a中的基团,其中m为0、1或2,R.sub.a为可选取代的碳氢基团;或可选的功能修饰磺酸基,A代表可选取代的二价脂肪族碳氢基团,n为0或1,并且含有盐基团的这种化合物的药物可接受的盐,用于治疗肝病、呼吸道疾病和血管疾病的制药制剂,其中包含式I的化合物和式I的新化合物。这些化合物具有保护肝脏和免疫调节作用。